# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Texas court rules against Humana, upholding Medicare Advantage bonus cuts and risking billions in insurer revenue tied to star ...
Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:ELV) with a Equal-Weight and raises the price target from...
Goldman Sachs analyst Scott Fidel initiates coverage on Elevance Health (NYSE:ELV) with a Neutral rating and announces Pric...
B of A Securities analyst Kevin Fischbeck maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target fr...
Mizuho analyst Ann Hynes maintains Elevance Health (NYSE:ELV) with a Outperform and raises the price target from $342 to $420.
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $373 to ...
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $360 to $...